Drug intelligence / Profile preview

AB-161

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral

Overview

AB-161 is an oral, liver-centric **small-molecule** hepatitis B virus therapeutic being developed for chronic HBV infection. It functions as a **PAPD5/7 inhibitor** and **HBV RNA destabilizer**, reducing viral RNA stability and lowering hepatitis B surface antigen concentrations; the provided data specifically note potent HBsAg lowering activity with an EC50 of 2.2 nM. The disclosed chemical identity is (S)-5-(tert-Butyl)-11-(difluoromethoxy)-9-methoxy-2-oxo-1,2,5,6-tetrahydropyrido[2',1':2,3]imidazo[4,5-h]quinoline-3-carboxylic acid, CAS 2848560-66-5.

Targets

TENT4BTENT4A (Terminal nucleotidyltransferase 4A)

Beyond the preview

Go deeper on AB-161.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB-161.

Explore the full profile